Alphamab Oncology is a biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange, with the stock code:9966.
To make cancer manageable and curable，Alphamab Oncology has always been guided by clinical value and patient needs, and focuses on the development of innovative, safe and affordable anti-tumor drugs.
We have created biomacromolecule platforms with independent intellectual property rights for drug discovery, research, development and manufacturing. Based on which, we can realize protein/antibody engineering, antibody screening, multi-module/multi-functional antibody modification.
With advanced technology platforms, Alphamab Oncology has established a globally competitive and differentiated pipeline which covers single domain antibody/monoclonal antibodies, multi-functional antibodies, and antibody-drug conjugates.
Located in Suzhou Industrial Park, the R&D and industrialization base covers an area of 75 acres and a total design scale of over 40,000 liters, was built in accordance with the NMPA, FDA and EMA GMP standards. The Phase I production line has obtained the production license and passed the audit of EU QP and US customers, which can provide safe, effective innovative drugs with controllable cost for cancer patients.
